Search Result

Results for "

FXR agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FXR (79) Akt (1) Aminotransferases (Transaminases) (1) AMPK (1) Antibiotic (1) Apoptosis (5) Autophagy (21) Bacterial (1) Calcium Channel (1) Cytochrome P450 (2) Drug Metabolite (2) Endogenous Metabolite (3) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (1) G protein-coupled Bile Acid Receptor 1 (8) Glutathione Reductase (GR) (1) HBV (1) Heme Oxygenase (HO) (1) Insecticide (2) Isotope-Labeled Compounds (5) Keap1-Nrf2 (1) LXR (3) mTOR (1) p38 MAPK (1) PD-1/PD-L1 (1) Phosphatase (1) PI3K (1) PPAR (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (2) Reference Standards (8) ROR (2) TNF Receptor (2) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (9) Endocrinology (1) Infection (4) Inflammation/Immunology (41) Metabolic Disease (37) Neurological Disease (2)

By Targets:

FXR (79)

Akt (1)

Aminotransferases (Transaminases) (1)

AMPK (1)

Antibiotic (1)

Apoptosis (5)

Autophagy (21)

Bacterial (1)

Calcium Channel (1)

Cytochrome P450 (2)

Drug Metabolite (2)

Endogenous Metabolite (3)

ERK (1)

Estrogen Receptor/ERR (1)

Ferroptosis (1)

G protein-coupled Bile Acid Receptor 1 (8)

Glutathione Reductase (GR) (1)

HBV (1)

Heme Oxygenase (HO) (1)

Insecticide (2)

Isotope-Labeled Compounds (5)

Keap1-Nrf2 (1)

LXR (3)

mTOR (1)

p38 MAPK (1)

PD-1/PD-L1 (1)

Phosphatase (1)

PI3K (1)

PPAR (1)

Quinone Reductase (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (8)

ROR (2)

TNF Receptor (2)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (12)

Cardiovascular Disease (9)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (41)

Metabolic Disease (37)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: FXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0172

Lithocholic acid Maximum Cited Publications 20 Publications Verification 3α-Hydroxy-5β-cholanic acid	Autophagy Endogenous Metabolite Apoptosis FXR	Metabolic Disease Inflammation/Immunology Cancer
Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a *FXR* antagonist and a PXR/SXR agonist .

HY-50108

GW 4064 55+ Cited Publications	FXR Autophagy	Metabolic Disease Cancer
GW 4064 is a potent *FXR* agonist with an EC₅₀ of 65 nM.

HY-12222

Obeticholic acid Maximum Cited Publications 85 Publications Verification INT-747; 6-ECDCA; 6-Ethylchenodeoxycholic acid	FXR Autophagy	Others
Obeticholic acid (INT-747) is a potent, selective and orally active *FXR* agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-10626

T0901317 40+ Cited Publications	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates *FXR* with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-10912

Fexaramine 5+ Cited Publications	FXR Autophagy	Others
Fexaramine is a potent and selective *FXR* agonist with an EC₅₀ of 25 nM. Fexaramine has no activity against hRXRα, hPPARαγδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ, and hVDR receptors .

HY-109083

Cilofexor 5+ Cited Publications GS-9674	FXR Autophagy	Inflammation/Immunology
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal *FXR* agonist with an EC₅₀ of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .

HY-107418

Tropifexor 5+ Cited Publications LJN452	FXR Autophagy	Cardiovascular Disease
Tropifexor (LJN452) is a highly potent agonist of *FXR* with an EC₅₀ of 0.2 nM .

HY-N4067

Isochenodeoxycholic acid isoCDCA	FXR Endogenous Metabolite	Metabolic Disease
Isochenodeoxycholic acid (isoCDCA) is a *FXR* agonist. Isochenodeoxycholic acid activates the activity of *FXR* and induces the mRNA expression of *FXR* target genes (Ostβ and Kng1). Isochenodeoxycholic acid serves as a substrate for the liver class I ADH γγ isozyme-mediated 3β-dehydrogenation reaction .

HY-50911

Turofexorate isopropyl 3 Publications Verification FXR-450; XL335; WAY-362450	FXR Autophagy	Metabolic Disease Cancer
Turofexorate isopropyl (FXR-450) is a potent, selective, and orally bioavailable *FXR* agonist with EC₅₀ of 4 nM .

HY-109197

Vonafexor 2 Publications Verification EYP001	FXR HBV	Infection
Vonafexor (EYP001) is an orally active, non-steroidal and selective *FXR* agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research .

HY-160929

Linafexor CS-0159	FXR	Inflammation/Immunology
Linafexor (CS-0159) is a *FXR* agonist and bile acid homeostasis modulator. Linafexor exerts its effects by activating FXR, a regulator of liver function. Linafexor is applicable to research related to primary sclerosing cholangitis (PSC). Linafexor is also suitable for research in the field of metabolic dysfunction-associated steatohepatitis (MASH) .

HY-B0172R

Lithocholic acid (Standard) Maximum Cited Publications 20 Publications Verification 3α-Hydroxy-5β-cholanic acid (Standard)	Reference Standards Autophagy Endogenous Metabolite Apoptosis FXR	Metabolic Disease Cancer
Lithocholic acid (Standard) is the analytical standard of Lithocholic acid. This product is intended for research and analytical applications. Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist .

HY-151932

FXR agonist 3 1 Publications Verification	FXR	Inflammation/Immunology
FXR agonist 3 is an anti-NASH agent, acting by activating *FXR. FXR* agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .

HY-12434

INT-767 5+ Cited Publications	FXR G protein-coupled Bile Acid Receptor 1 Autophagy	Cancer
INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC₅₀s of 30 and 630 nM, respectively .

HY-N3431

Kaempferol-7-O-rhamnoside	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)	Cardiovascular Disease
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-109096

Nidufexor LMB763	FXR Autophagy	Inflammation/Immunology
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH) .

HY-101273

BAR502	G protein-coupled Bile Acid Receptor 1 FXR Autophagy	Neurological Disease Inflammation/Immunology
BAR502 is a dual *FXR* and GPBAR1 agonist with IC₅₀ values of 2 μM and 0.4 μM, respectively.

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

HY-147296

Omesdafexor MET409	FXR	Inflammation/Immunology Cancer
Omesdafexor (MET409) is an orally active *FXR* agonist with a unique non-bile acid structure. Omesdafexor can be used for the study of non-alcoholic steatohepatitis (NASH) .

HY-N4294

Arjungenin	FXR Insecticide	Infection Metabolic Disease Inflammation/Immunology
Arjungenin, a pentacyclic triterpenoid compound, is a *FXR* agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV) .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an *FXR* antagonist to combat obesity and insulin resistance .

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-142159

FXR/TGR5 agonist 1	FXR G protein-coupled Bile Acid Receptor 1	Metabolic Disease
FXR/TGR5 agonist 1 has agonist action on *FXR* and TGR5, and can be used for the research of fatty liver disease.

HY-169792

HPG1860	FXR Aminotransferases (Transaminases)	Metabolic Disease Inflammation/Immunology
HPG1860 is an orally active, highly selective and potent *FXR* agonist, with an EC₅₀ of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC₅₀ values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .

HY-164799

FXR agonist 12	FXR	Inflammation/Immunology
FXR agonist 12 (Compound C7) is the orally active agonist for *FXR. FXR* agonist 12 down-regulates bile acid synthesis-related genes, and up-regulates bile acid transport-related genes in HepG2 cells. FXR agonist 12 improves ANIT-induced cholestasis, ameliorates the liver damage and fibrosis in mouse NASH models .

HY-135399

Tauro-obeticholic acid	FXR	Inflammation/Immunology
Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-N3209

Nelumol A	FXR	Inflammation/Immunology
Nelumol A is a farnesoid X receptor (FXR) agonist .

HY-100443A

trans-PX20606 3 Publications Verification trans-PX-102	FXR Autophagy	Metabolic Disease
PX20606 trans racemate (PX-102 trans racemate) is a *FXR* agonist with EC₅₀s of 32 and 34 nM for FXR in FRET and M1H assay, respectively .

HY-103704

LY2562175	FXR Autophagy	Metabolic Disease
LY2562175 is a potent and selective *FXR* agonist, with an EC₅₀ of 193 nM .

HY-N3891

Fargesone A	FXR	Inflammation/Immunology
Fargesone A is a potent and selective *FXR* agonist. Fargesone A shows anti-inflammatory activity .

HY-12222R

Obeticholic acid (Standard) INT-747 (Standard); 6-ECDCA (Standard); 6-Ethylchenodeoxycholic acid (Standard)	Reference Standards FXR Autophagy	Others
Obeticholic acid (Standard) is the analytical standard of Obeticholic acid. This product is intended for research and analytical applications. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-139418

PX20350	FXR	Cancer
PX20350 is a *FXR* agonist with EC₅₀s of 83 and 10 nM for mFXR and hFXR, respectively. PX20350 significantly induces NDRG2 mRNA expression. PX20350 potently reduces liver tumor cells (SK-GI-18 cells) growth and metastasis, and has anti-tumorigenic activity in orthotopic xenograft mouse models .

HY-153525

FXR agonist 5	FXR	Metabolic Disease Inflammation/Immunology
FXR agonist 5 (compound 1) is a *FXR* agonist. FXR agonist 5 can be used for research in diseases or disorders caused by metabolic inflammation .

HY-163466

FXR agonist 7	FXR	Inflammation/Immunology
FXR agonist 7 (compound 33) is a potent agonist of *FXR, with EC₅₀* of 0.1 nM. FXR agonist 7 shows high intestinal distribution, good anti-inflammatory activity .

HY-178959

FXR agonist 13	FXR	Metabolic Disease Inflammation/Immunology
FXR agonist 13 is a selective, orally active, potent *FXR* agonist (EC₅₀ = 0.097 μM) and has favorable hepatic microsomal metabolic stability. FXR agonist 13 exhibits moderate affinity for FXR-LBD upon direct binding (K_D = 14.74 μM). FXR agonist 13 displays good selectivity against related nuclear receptors, including LXRα/β, PPARα/γ/δ, PXR, and TGR5. FXR agonist 13 can be used for the study of metabolic-associated steatohepatitis (MASH) .

HY-168332

FXR agonist 11	FXR	Metabolic Disease
FXR agonist 11 (Compound 14) is an *FXR* agonist with an EC₅₀ of 1.2 μM and a maximum effect of 73.7%. FXR agonist 11 can significantly increase GSH levels in the liver and is used to study drug-induced liver injury diseases .

HY-175516

*dual FXR/PPARδ agonist-2*	FXR PPAR	Inflammation/Immunology
dual FXR/PPARδ agonist-2 is a FXR/PPARδ dual agonist through hybridation of FXR agonist GW-4064 and PPARδ agonist GW-0742.dual FXR/PPARδ agonist-2 displays potent dual-target activities with a FXR agonistic EC₅₀ of 12.28 nM and 69 % PPARδ activation at 100 nM. dual FXR/PPARδ agonist-2 shows anti-fibrotic effects in pulmonary fibrosis mouse model .

HY-168629

FXR agonist 9	FXR	Metabolic Disease
FXR agonist 9 (compound 26) is an oral active and selectivity *FXR* partial agonist with the EC₅₀ of 0.09 µM (75.13 % maximum efficacy). FXR agonist 9 ameliorates pathological features in HFD and CCl₄(HY-Y0298)-induced metabolic dysfunction-associated steatohepatitis mice .

HY-W587537

Deoxycholic acid 3-O-β-D-glucuronide disodium	FXR	Metabolic Disease
Deoxycholic Acid 3-O-beta-D-Glucuronide disodium salt is a bile acid receptor (FXR) agonist.

HY-100443

PX20606 PX-102	FXR	Cancer
PX20606 is an orally active agonist for farnesoid X receptor (FXR), with EC₅₀ 220 nM (mFXR) and 50 nM (hFXR), measured by Gal4-FXR assay. PX20606 induces the expression of tumor suppressor gene NDRG2, inhibits the tumor growth and metastasis in mouse HCC model. PX20606 exhibits hepatoprotective efficacy .

HY-N10640

Alismanol M	FXR	Inflammation/Immunology
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .

HY-W587451

Cholic acid 3-O-glucuronide disodium OCA-3-glucuronide disodium	FXR	Metabolic Disease
Cholic acid 3-O-glucuronide (OCA-3-glucuronide) disodium is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 91.5 μM. Cholic acid 3-O-glucuronide is promising for research of bile acid metabolism and detoxification .

HY-12222S

Obeticholic acid-d5 INT-747-d₅; 6-ECDCA-d₅; 6-Ethylchenodeoxycholic acid-d₅	FXR Autophagy	Others
Obeticholic acid-d₅ is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-113567

GSK2324	FXR	Metabolic Disease
GSK2324 (Compd 1c) is a *FXR* agonist for diabetes study, with an EC₅₀ of 120 nM. GSK2324 exhibits t_1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively .

HY-179278

*LXR agonist* 4**	LXR	Cardiovascular Disease Metabolic Disease Endocrinology
LXR agonist 4 is a selective LXR inverse agonist with IC₅₀ values of 7.6 (LXRα) and 2.9 μM (LXRβ), respectively. LXR agonist 4 exhibits selectivity over RORα and *FXR. LXR agonist* 4 robustly suppresses SREBP1c expression without altering ABCA1 or APOE. LXR agonist 4 displays antilipogenic properties and resolves fatty acid-induced steatosis. LXR agonist 4 can be used for the research of atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD) .

HY-10626R

T0901317 (Standard)	Reference Standards LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-153114

HEC96719	FXR	Inflammation/Immunology
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .

HY-125996

NR1H4 activator 1	FXR	Inflammation/Immunology
NR1H4 activator 1 is a potent and selective Famesoid X Receptor (FXR) agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC₅₀ value of 1 nM in a Human FXR (NR1H4) Assay. NR1H4 activator 1 has the potential for treatment of gastrointestinal disease .

HY-181761

FXR agonist 16	FXR	Metabolic Disease
FXR agonist 16 is a *FXR* agonist with an EC₅₀ of 2.2 μM. FXR agonist 16 activates FXR transcriptional activity, upregulates SHP and BSEP, and downregulates Cyp7a1. FXR agonist 16 exhibits hepatoprotective activity and reduces AST and ALT levels in free fatty acid-induced hepatocellular injury models. FXR agonist 16 can be used for the research of liver injury .

HY-180221

FXR agonist 14	FXR	Metabolic Disease
FXR agonist 14 (Compound V15) is a partial, selective, orally active *FXR* agonist with an EC₅₀ of 0.67 nM. FXR agonist 14 ameliorates pathological features in high-fat and high-sugar diet-induced MASH mice. FXR agonist 14 shows significant anti-cholestatic liver disease effects .

Cat. No.	Product Name	Target	Research Area

HY-A0248BR

Polymyxin B2 (Standard)	Reference Standards Antibiotic Bacterial	Infection
Obeticholic acid (Standard) is the analytical standard of Obeticholic acid. This product is intended for research and analytical applications. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0172

Lithocholic acid Maximum Cited Publications 20 Publications Verification 3α-Hydroxy-5β-cholanic acid	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Anti-aging Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Autophagy Endogenous Metabolite Apoptosis FXR
Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a *FXR* antagonist and a PXR/SXR agonist .

HY-N4067

Isochenodeoxycholic acid isoCDCA	Source Classification	FXR Endogenous Metabolite
Isochenodeoxycholic acid (isoCDCA) is a *FXR* agonist. Isochenodeoxycholic acid activates the activity of *FXR* and induces the mRNA expression of *FXR* target genes (Ostβ and Kng1). Isochenodeoxycholic acid serves as a substrate for the liver class I ADH γγ isozyme-mediated 3β-dehydrogenation reaction .

HY-B0172R

Lithocholic acid (Standard) Maximum Cited Publications 20 Publications Verification 3α-Hydroxy-5β-cholanic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Anti-aging Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Reference Standards Autophagy Endogenous Metabolite Apoptosis FXR
Lithocholic acid (Standard) is the analytical standard of Lithocholic acid. This product is intended for research and analytical applications. Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist .

HY-N3431

Kaempferol-7-O-rhamnoside	Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Chimonanthus nitens Oliv. Plants Disease Research Fields Source Classification Calycanthaceae	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-N4294

Arjungenin	Triterpenes Classification of Application Fields Terpenoids Combretaceae Metabolic Disease Terminalia chebula Retz. Plants Disease Research Fields Source Classification	FXR Insecticide
Arjungenin, a pentacyclic triterpenoid compound, is a *FXR* agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV) .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an *FXR* antagonist to combat obesity and insulin resistance .

HY-N3209

Nelumol A	Ketones, Aldehydes, Acids Tamarindus indica L. Plants Compositae Source Classification	FXR
Nelumol A is a farnesoid X receptor (FXR) agonist .

HY-N3891

Fargesone A	Magnoliaceae Lignans Yulania biondii (Pamp.) D. L. Fu Phenylpropanoids Plants Source Classification	FXR
Fargesone A is a potent and selective *FXR* agonist. Fargesone A shows anti-inflammatory activity .

HY-N10640

Alismanol M	Triterpenes Terpenoids Alisma orinentale (Samuel.) Juz. Plants Alismataceae	FXR
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .

HY-N15305

Ferolin	Other Terpenoids Terpenoids Apiaceae Plants Ferula lapidosa Korovin Source Classification	FXR
Ferolin is the agonist for farnesoid X receptor (FXR) with an EC₅₀ of 0.56 µM. Ferolin inhibits the expression of inflammatory genes (such as iNOS, IL-1β and TNFα) upon the FXR activation .

HY-N4294R

Arjungenin (Standard)	Triterpenes Terpenoids Combretaceae Terminalia chebula Retz. Plants Source Classification	Reference Standards FXR Insecticide
Arjungenin (Standard) is the analytical standard of Arjungenin. This product is intended for research and analytical applications. Arjungenin, a pentacyclic triterpenoid compound, is a *FXR* agonist. Arjungenin can improve insulin sensitivity by regulating the function of fat cells. Arjungenin exhibits moderate free radical scavenging activity. Arjungenin has growth inhibitory activity against the insect Spilarctia obliqua. Arjungenin has significant antiviral activity against a series of viruses such as chikungunya Virus (CHIKV).

HY-N1749

2-Oxokolavenol	Structural Classification Terpenoids Aglaia lawii (Wight) C. J. Saldanha & Ramamorthy Diterpenoids Plants Meliaceae Source Classification	FXR
2-Oxokolavenol is a selective agonist targeting the farnesoid X receptor (FXR), with an EC₅₀ of ~3.7 μM. 2-Oxokolavenol exerts its activity against Acetaminophen (HY-66005)-induced hepatocyte damage in an FXR-dependent manner by binding to the FXR ligand-binding pocket, recruiting co-activators, and inducing FXR transcriptional activity. 2-Oxokolavenol can be naturally extracted from Aglaia spectabilis (a plant of the Aglaia genus in the Meliaceae family) and can be used in research related to liver diseases .

Cat. No.	Product Name	Chemical Structure

HY-12222S

Obeticholic acid-d5
Obeticholic acid-d₅ is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-135400S

Glyco-obeticholic acid-d5
Glyco-obeticholic acid-d₅ is the deuterium labeled Glyco-Obeticholic acid. Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .

HY-12365S2

Tauro-obeticholic acid-d5
Tauro-obeticholic acid-d₅ is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-135399S

Tauro-obeticholic acid-d5 sodium
Tauro-obeticholic acid-d₅ sodium is deuterium labeled Tauro-obeticholic acid sodium (HY-135399A). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-W653920

Tauro 6-ethlchenodeoxycholic acid-d5(sodium）
Tauro 6-ethlchenodeoxycholic acid-d₅ sodium is deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

HY-12222S1

Obeticholic acid-d4-1
Obeticholic Acid-d₄ is the deuterium labeled Obeticholic acid. Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC₅₀ of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy .

HY-135400S2

Glyco-obeticholic acid-d4
Glyco-obeticholic acid-d₄ is the deuterium labeled Glyco-obeticholic acid (HY-135400). Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist .

HY-135399S2

Tauro-obeticholic acid-d4
Tauro-obeticholic acid-d₄ is the deuterium labeled Tauro-obeticholic acid (HY-135399). Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks